Arca
Skip to content
Tools
Tools

Hypoparathyroidism

Drug research and approvals for hypoparathyroidism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 36 studies of hypoparathyroidism are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 3 approved and 6 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 36
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 3
  • EU medicines: 1

Recruiting now

Newest posted first, of 36 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 1

Phase 2 1

Phase 1 or earlier 3

How its trials ended

100 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 21 whose ending is known, 62% met their primary endpoint, 5% missed it and 33% stopped early.

  • Completed, result not reported3838%
  • Ongoing2727%
  • Status unknown1414%
  • Met its primary endpoint1313%
  • Stopped: other or unclear33%
  • Stopped: sponsor or business decision22%
  • Missed its primary endpoint11%
  • Stopped: enrollment or feasibility11%
  • Stopped: funding11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 11, 2026A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension investigating efficacy, safety, and…EncaleretCalcilytix Therapeutics IncPending
May 11, 2023A phase 3 multi center, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (AZP3601), a parathyroid…Eneboparatide (AZP-3601)AstraZeneca PharmaceuticalsOngoing
Dec 1, 2020Pathway trial: a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with an open-label extension, investigating the…Palopegteriparatide (transcon pth)Ascendis PharmaClosed
Apr 20, 2020A randomized, double-blind, multiple ascending oral dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PCO371 in…PCO371Chugai PharmaceuticalOngoing
May 9, 2019Path forward: a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group trial with an open-label extension, investigating the…Palopegteriparatide (transcon pth)Ascendis PharmaClosed
Dec 20, 2018A randomized, double-blind, placebo-controlled, adaptive study to evaluate symptom improvement and metabolic control among adult subjects with symptomatic…RHPTH(1-84) (recombinant human parathyroid hormone)Takeda Pharmaceuticals USAClosed
Mar 1, 2018An open-label study investigating the safety and efficacy of rhpth (1-84) in subjects with hypoparathyroidismRhpth (1-84)Takeda Pharmaceuticals USAPending
Dec 22, 2017Open-label, randomized, crossover study to assess the pk and pd profiles of once-daily and twice-daily dose regimens of recombinant human parathyroid hormone…RHPTH(1-84)Takeda Pharmaceuticals USAOngoing

FDA orphan designations

Approved first, then open designations, newest first
Aug 9, 2024YorvipathTreatment of hypoparathyroidism in adultsAscendis Pharma Bone Diseases A/SApproved
Jan 23, 2015NatparaAn adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidismTakeda Pharmaceuticals U.S.A., Inc.Approved
Dec 23, 1987ParatharDiagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due…Rhone-Poulenc Rorer Pharmaceuticals, Inc.Approved
Jul 25, 2022Fatty acylated parathyroid (prodrug) hormone agonistTreatment of hypoparathyroidismMBX BiosciencesDesignated
May 25, 2022PTH(1-34)-Cys(succinimido-PEG-vitamin D) amide (human)…Treatment of hypoparathyroidismExtend Biosciences Inc.Designated
Dec 14, 2020H-Ala-Val-Ala-Glu-Ile-Gln-Leu-Met-His-Gln-Arg-Ala-Lys-Trp-Il…Treatment of HypoparathyroidismAmolyt Pharma SAS (formerly Alize Pharma III SAS)Designated
Dec 15, 2014Non-peptide small molecule orally available agonist of the…Treatment of hypoparathyroidismChugai Pharma USA, LLCDesignated
Apr 18, 2014TeriparatideTreatment of hypoparathyroidismEntera Bio, Ltd.Designated
Jan 26, 2001Synthetic Human Parathyroid Hormone 1-34Treatment of hypoparathyroidismRare Disease Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 17, 2023YorvipathPalopegteriparatide · orphanAscendis Pharma Bone Diseases A/SEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.